StreetAlpha.app
Home › Stocks › ACRS

Aclaris Therapeutics, Inc. (ACRS)

Healthcare
$3.38
▼ −6.24%
LAST CLOSE · NOV 17

Aclaris Therapeutics develops prescription drug candidates, testing them in clinical trials and planning to sell approved products through partners. It last closed at $3.38 on Nov 17, down 6.24% on the day. The average 12-month price target from 2 analysts is $7.50 (+121.9% from the last close), with a high of $12.00 and a low of $3.00.

AI Auto Pilots
Is ACRS in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$6.4M
−59.3% vs a year ago
Net income
−$79.6M
−1244.1% margin
EPS (diluted)
−$0.59
Free cash flow
−$75.3M
−1176.6% margin
Valuation
Market cap
$536.1M
158.6M shares
P/E
–
No P/E while losing money
Price to sales
83.8
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$20.4M
At Sep 30
Shareholder equity
$166.8M
Shares outstanding
158.6M
At Oct 30
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $6.8M$6.8MFY2021FY2022: $29.8M$29.8MFY2022FY2023: $31.2M$31.2MFY2023FY2024: $18.7M$18.7MFY2024FY2025: $7.8M$7.8MFY2025

From ACRS's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.

Last report
Nov 5
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
1 Buy · 1 Hold
2 firms · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
1 Buy · 1 Hold
2firms
1 Buy1 Hold0 Sell
Only 2 firms rated ACRS in the past 90 days, not enough for a consensus
Average 12-month target
$7.50
▲ 121.9% upside

Based on 2 analysts who set a price target on ACRS in the past 90 days. The average target is $7.50, with a high of $12.00 and a low of $3.00, compared with the last close of $3.38.

Low $3.00Avg $7.50High $12.00
Blue marker: last close $3.38
Highest target$12.00
Average target$7.50
Lowest target$3.00
Latest rating changes
Canaccord GenuityTarget lowered
Nov 17Buy$13 → $12
WedbushDowngrade
Nov 17Hold$3
Canaccord GenuityTarget raised
Oct 31Buy$10 → $13
Canaccord GenuityInitiated
Sep 1Buy$10
LifeSci CapitalInitiated
Jun 2Buy$13
DateFirmActionRatingPrice target
Nov 17Canaccord GenuityTarget loweredBuy$13 → $12
Nov 17WedbushDowngradeHold$3
Oct 31Canaccord GenuityTarget raisedBuy$10 → $13
Sep 1Canaccord GenuityInitiatedBuy$10
Jun 2LifeSci CapitalInitiatedBuy$13
Loading…

Technical Analysis

ACRS · as of the Nov 17 close · updated after every close
Downtrend, nearing oversold

The stock is 14% below its 20 day and 28% below its 50 day average. It is 34% below its 200 day average, so the longer trend is down. Momentum is fading (RSI 37), near oversold. The nearest support is the Pivot S1 at $3.28, and the nearest resistance the Pivot at $3.42.

Short trendBearish
Long trendBearish
MomentumFading
StretchNear oversold
VolatilityHigh, 9.4%/day
Key levels
$6.6052 week high+95.3%
$5.05100 day average+49.4%
$4.54200 day average+34.3%
$4.3350 day average+28.1%
$4.08Swing high (Oct 29)+20.7%
$3.8620 day average+14.2%
$3.52Pivot R1+4.1%
$3.42Pivot+1.2%
$3.38Last close
$3.28Pivot S1−3.0%
$3.25Swing low (Oct 16)−3.8%
$2.3452 week low−30.8%
Indicators
RSI (14)36.93Weak, oversold below 30Neutral
MACD-0.12Above its signal lineBullish
Stochastic27.8Middle of its rangeNeutral
ADX (14)29.5Trending down
Williams %R-93.6Oversold below −80, overbought above −20Oversold
CCI (20)-184.4Oversold below −100, overbought above 100Oversold
Rate of change−9.6%Change over 10 sessionsBearish
ATR (14)$0.32Typical daily range, 9.4% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for ACRS

What happened before

See how ACRS did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow ACRS usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How ACRS has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2015.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in ACRS in the last 90 days.

Loading…

See today’s whale options flow across the market →

ACRS Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲95 buying vs 62 selling
  • ▲Held by funds +10.9 pts
  • ▲Funds holding +18
  • ▼Superinvestors: 1 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding167149+12.1%
In funds' top 1065+20.0%
Held by funds87.3%76.4%+10.9 pts
New / increased38 / 5728 / 68−1.0%
Reduced / sold out41 / 2131 / 14+37.8%
Put/call ratio0.000.00–
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See ACRS institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ACRS is in one of them and how their past ACRS trades turned out.

ACRS in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered ACRS in an article yet. Here's the latest on the wider market.

About Aclaris Therapeutics

Aclaris Therapeutics is a pharmaceutical company based in Wayne, Pennsylvania. It develops prescription drug product candidates and tests them in clinical trials, relying on outside research organizations to run much of that work. The company plans to bring approved products to patients through outside partners, who would sell them to patients, insurers and government health programs. It also depends on outside suppliers to manufacture the drug supplies used in its trials.

Headquarters
Wayne, PA